Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

News SummaryMost relevantAll newsSector newsTweets

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

   By Saabira Chaudhuri 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
10/19 ELI LILLY AND : VERZENIOTM abemaciclib Approved for Treatment of Metastatic Brea..
10/19ELI LILLY AND CO : quaterly earnings release
10/18DJELI LILLY AND : Lilly To Develop Cancer Vaccine Products with CureVac -- Market ..
10/18 ELI LILLY AND : Lilly and CureVac Announce Global Collaboration to Develop mRNA ..
10/17 ELI LILLY AND : The GOP’s Tax Reform Framework is a Step in the Right Dire..
10/16 ELI LILLY AND : Lilly Declares Fourth-Quarter 2017 Dividend
10/16 ELI LILLY AND : Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients..
10/13 ELI LILLY AND : Open Enrollment is in Season
10/13 ELI LILLY AND : Overcoming Communication Barriers with Metastatic Breast Cancer ..
10/13 ELI LILLY AND : VERZENIO Approved for Treatment of Metastatic Breast Cancer, Ava..
More news
News from SeekingAlpha
10/18 Lilly teams up with CureVac to develop cancer vaccines based on mRNA technolo..
10/16 Eli Lilly declares $0.52 dividend
10/16 BIOTECH FORUM DAILY DIGEST : Aratana Therapeutics Back In The Spotlight
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 SANOFI : Upward Trajectory In 2017
Financials ($)
Sales 2017 22 499 M
EBIT 2017 5 592 M
Net income 2017 2 690 M
Debt 2017 6 621 M
Yield 2017 2,44%
P/E ratio 2017 38,54
P/E ratio 2018 21,07
EV / Sales 2017 4,49x
EV / Sales 2018 4,34x
Capitalization 94 388 M
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 91,0 $
Spread / Average Target 6,2%
EPS Revisions
David A. Ricks Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
Franklyn G. Prendergast Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372